Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial

Purpose To examine the efficacy and safety of triple therapy with eribulin, trastuzumab, and pertuzumab in patients with HER2-positive metastatic breast cancer (MBC) who never received any prior therapy in the first-line metastatic/advanced setting. Methods Eribulin 1.4 mg/m(2) (days 1 and 8), trast...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Kenichi, Ninomiya, Jun, Saito, Tsuyoshi, Okubo, Katsuhiko, Nakakuma, Takashi, Yamada, Hirofumi, Kimizuka, Kei, Higuchi, Tohru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538821/
https://www.ncbi.nlm.nih.gov/pubmed/30848403
http://dx.doi.org/10.1007/s10637-019-00755-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538821/
https://www.ncbi.nlm.nih.gov/pubmed/30848403
http://dx.doi.org/10.1007/s10637-019-00755-x

Ejemplares similares